Factors associated with blood pressure in end stage renal disease patients receiving regular hemodialysis at Wangaya general hospital, Denpasar

I. Kadek Aditya Nugraha, Theodore Dharma Tedjamartono, Wayan Sunaka


Background: Hypertension is common findings in end-stage renal disease (ESRD) patients receiving hemodialysis, around two third among them are poorly controlled. We analyzed factors affecting blood pressure in patients undergoing regular hemodialysis.

Methods:A single center cross-sectional study conducted including 65 patients receiving regular hemodialysis at hemodialysis unit Wangaya general hospital, Bali, Indonesia. Ordinal regression test was performed to analyze the relationship between factor associated with blood pressure in regular hemodialysis patients.

Results: Among subjects included, 64 (98.5%) subject had hypertension and 22 (34.4%) subjects had well controlled blood pressure (<140/90 mmHg), 20 (31.3%) subjects had blood pressure between 140/90 to 160/100 mmHg and 22 (34.4%) subjects had blood pressure >160/100 mmHg. Univariate analysis showed statistically significant associated factors were higher number of antihypertensive medications (p=0.002), higher level of hemoglobin (p=0.008), hematocrit (p=0.012) and urea (p=0.041). Multivariate analysis showed higher amount of anti-hypertensive medications and year of dialysis were statistically significant associated with blood pressure in regular hemodialysis patients.

Conclusions:Significant factors associated with blood pressure in regular hemodialysis patients were higher amount of anti-hypertensive medications and increased year of dialysis. 



ESRD, Hemodialysis, Blood pressure, Hypertension

Full Text:



Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:1-290.

Shafiee MA, Chamanian P, Shaker P, Shahideh Y, Broumand B. The impact of hemodialysis frequency and duration on blood pressure management and quality of life in end-stage renal disease patients. Healthcare (Basel, Switzerland). 2017;5(3):52.

Heerspink HJL, Ninomiya T, Zoungas S, Zeeuw DD, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (London, England). 2009;373(9668):1009-15.

Konta T, Ikeda A, Ichikawa K, Fujimoto S, Iseki K, Moriyama T, et al. Blood pressure control in a japanese population with chronic kidney disease: a baseline survey of a nationwide COHORT. Am J Hypertens. 2012;25(3):342-7.

Sarafidis PA, Persu A, Agarwal R, Burnier M, Leeuw PD, Ferro CJ, et al. Hypertension in dialysis patients: a consensus document by the european renal and cardiovascular medicine (EURECA-m) working group of the european renal association–european dialysis and transplant association (ERA-EDTA) and the hypertension and the kidney. Nephrol Dial Transplant. 2017;32(4):620-40.

Iseki K, Nakai S, Shinzato T, Morita O, Shinoda T, Kikuchi K, et al. Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dial. 2007;11(3):183-8.

Nemati E, Ghanbarpour F, Taheri S, Einollahi B. Prevalence of hypertension among Iranian hemodialysis patients and associated risk factors: a nationwide multicenter study. Pakistan J Biol Sci. 2008;11(6):910-4.

Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006;17:1-27.

Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, et al. Japanese society for dialysis therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial. 2012;16(5):387-435.

Hsu H, Robinson C, Norton GR, Woodiwiss AJ, Dessein PH. The optimal haemoglobin target in dialysis patients may be determined by its contrasting effects on arterial stiffness and pressure pulsatility. Int J Nephrol Renovasc Dis. 2020;13:385-95.

Jae SY, Kurl S, Laukkanen JA, Heffernan KS, Choi YH, Park JB. High blood hematocrit increases the risk of the incidence of hypertension in men. Eur Heart J. 2013;34(1):4461.

Emamian M, Hasanian SM, Tayefi M, Bijari M, Far FM, Shafiee M, et al. Association of hematocrit with blood pressure and hypertension. J Clin Lab Anal. 2017;31(6):22124.

D’Apolito M, Du X, Pisanelli D, Pettoello-Mantovani M, Campanozzi A, Giacco F, et al. Urea-induced ROS cause endothelial dysfunction in chronic renal failure. Atherosclerosis. 2015;239(2):393-400.

Avramovski P, Janakievska P, Sotiroski K, Sikole A. Accelerated progression of arterial stiffness in dialysis patients compared with the general population. Korean J Intern Med. 2013;28(4):464.

Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291-7.

Kotanko P, Garg AX, Depner T, Pierratos A, Chan CT, Levin NW, et al. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. Hemodial Int. 2015;19(3):386-401.

Susantitaphong P, Koulouridis I, Balk EM, Madias NE, Jaber BL. Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis. Am J Kidney Dis. 2012;59(5):689-99.

Zheng X, Jin C, Liu Y, Zhang J, Zhu Y, Kan S, et al. Arterial Stiffness as a Predictor of clinical hypertension. J Clin Hypertens. 2015;17(8):582-91.

Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(3):35-40.

Tomiyama H, Shiina K, Matsumoto‐Nakano C, Ninomiya T, Komatsu S, Kimura K, et al. The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness. J Am Heart Assoc. 2017;6(7):5729.